ProCE Banner Activity

D-RVd vs RVd for Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma: Real-world Outcomes

Conference Coverage

Real-world single institution data from patients with newly diagnosed multiple myeloma treated with either D-RVd or RVd induction therapy was consistent with clinical trial data and showed improved response rates over time.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.